Health ‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib

CONCLUSIONSFor most patients, HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018. © 2018 American Cancer Society.

Source: Cancer - March 2, 2018 Category: Cancer & Oncology Authors: Fabio Efficace, Fausto Castagnetti, Bruno Martino, Massimo Breccia, Mariella D'Adda, Emanuele Angelucci, Fabio Stagno, Francesco Cottone, Alessandra Malato, Elena Trabacchi, Silvana Franca Capalbo, Marco Gobbi, Giuseppe Visani, Marzia Salvucci, Isabella C Tags: Original Article Source Type: research